Lilly Pushes Through $1,200 as Shorts Exit and Street Lifts Targets

The lending and positioning data reinforces the constructive read. Short interest is now under 1% of free float — sitting at 0.96% — and has fallen 12.5% on the week and 3.3% over the past month. That is a meaningful exodus of bearish conviction. Borrow costs reflect it: the cost to borrow has eased to just 0.28%, down 30% over the past month, touching the lowest levels of the observable 30-day window. Share availability is essentially uncapped — there is no shortage of supply for anyone still wanting to establish a short position. The ORTEX short score has slipped to 30.5 from 31.7 a week ago, the lowest in the recent history tracked, consistent with bears continuing to step back rather than reload. Overall, the lending market tells a story of shorts who came in defensively ahead of earnings and have since quietly exited.

Options tell a similar tale of de-escalation, but with one nuance worth watching. The put/call ratio is at 1.17 — now notably below its 20-day mean of 1.26, running about 1.3 standard deviations below average. That is the mirror image of the pre-earnings setup, when the PCR was at its 52-week high of 1.37 with a defensive z-score well above the norm. The hedges are not just unwound — options traders are now running meaningfully less defensive than their own recent baseline. That is either a sign of genuine conviction or a signal that the market has become complacent after the strong print; the data alone doesn't answer which.

The Street has not been shy about re-rating. In the five days after the Q2 report, Truist lifted its target to $1,376, Wells Fargo moved to $1,330 from $1,280, and Cantor Fitzgerald took its target to $1,410 from $1,350. The consensus price target now stands at $1,300 — roughly 7% above Tuesday's close — with the most bullish targets from Citi ($1,600) and UBS ($1,425) offering a wider range of outcomes than the consensus alone suggests. The bull case rests on GLP-1 franchise momentum, with the Q2 print delivering 58% year-over-year GLP-1 revenue growth and a projected revenue path toward $130 billion by 2033. Bears are less focused on the current quarter and more on pricing pressure on Zepbound and Trulicity, along with execution risk on tirzepatide and forglipron launches. On valuation, the trailing PE is running at 28.5x and the EV/EBITDA has eased to 22.9x — both ticking down modestly over the past 30 days, suggesting the multiple has compressed slightly even as the price has risen, driven by earnings upgrades flowing through. The factor score profile is supportive on EPS momentum (75th percentile over 30 days, 73rd over 90 days) and EPS surprise (76th), while the value score remains a clear weak point at the 35th percentile on EV/EBIT — the premium is still there, just slightly less extreme than before the print.

The next formal catalyst is October 29 Q3 earnings. Between now and then, the watch points are whether the Street's recently upgraded consensus holds as Q3 data comes into focus, whether the put/call ratio's current below-average reading sustains or reverts toward the protective posture that defined much of July, and whether short interest — now at its lowest level since mid-July — stabilises here or continues to bleed lower as the post-earnings reset completes.